Abstract
A double-blind controlled trial of a 14-valent pneumococcal polysaccharide vaccine was carried out in 11 958 adults at Tari in the Papua New Guinea Highlands. Pneumococcal infection, confirmed by blood-culture and lung aspirate, was less in the vaccinated group by 84%. Mortality from pneumonia was less by 44%.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Antibodies, Bacterial / isolation & purification
-
Bacterial Vaccines / administration & dosage
-
Bacterial Vaccines / therapeutic use*
-
Clinical Trials as Topic
-
Evaluation Studies as Topic
-
Follow-Up Studies
-
Humans
-
Lung / microbiology
-
New Guinea
-
Nose / microbiology
-
Pneumonia, Pneumococcal / microbiology
-
Pneumonia, Pneumococcal / mortality
-
Pneumonia, Pneumococcal / prevention & control*
-
Polysaccharides, Bacterial / administration & dosage
-
Polysaccharides, Bacterial / therapeutic use
-
Sepsis / microbiology
-
Sputum / microbiology
-
Streptococcus pneumoniae / immunology*
-
Streptococcus pneumoniae / isolation & purification
Substances
-
Antibodies, Bacterial
-
Bacterial Vaccines
-
Polysaccharides, Bacterial